{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:24:12Z","timestamp":1766805852278,"version":"3.44.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Rift Valley Fever virus (RVFV) is a mosquito-borne zoonotic pathogen, that causes significant morbidity and mortality in livestock, including high abortion rates in pregnant animals and elevated case fatality in neonates, representing a major threat to both animal and human health. Vaccination is the most effective countermeasure to reduce RVFV\u2019s impact. In this study, we designed a veterinary DNA vaccine encoding a consensus RVFV glycoprotein precursor (GPC), optimized for expression in sheep. The construct was evaluated for immunogenicity in mice and sheep and for protective efficacy in sheep raised under natural field conditions in Senegal, West Africa. The vaccine induced robust humoral responses characterized by high neutralizing antibody titers in both mice and sheep. Under natural exposure, vaccinated sheep showed reduced infection rates (3.2%) compared with controls (14.3%), and neutralizing antibody responses persisted for more than one year. Importantly, the vaccine was well tolerated, including in pregnant animals, with no adverse outcomes such as abortions or fetal abnormalities. These findings demonstrate that a DNA-based RVFV vaccine can elicit durable immunity and provide protection in livestock under real-world conditions. This study highlights the potential of DNA vaccines as a safe, effective, and affordable alternative to existing veterinary vaccines and supports their further development as a key strategy to reduce RVFV transmission and improve animal and human health outcomes in endemic regions.<\/jats:p>","DOI":"10.3389\/fcimb.2025.1628877","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:28:00Z","timestamp":1756186080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A DNA vaccine candidate provides protection against Rift Valley Fever virus in sheep under natural field conditions"],"prefix":"10.3389","volume":"15","author":[{"given":"Moufid","family":"Mhamadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George (Giorgi)","family":"Babuadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aminata","family":"Badji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Edith","family":"Nepveu-Traversy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El Hadji","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alioune","family":"Gaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mignane","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moundhir","family":"Mhamadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank William","family":"Mendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheikh Talibouya","family":"Tour\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idrissa","family":"Dieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moussa","family":"Dia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ndeye Sakha","family":"Bob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"de La Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ousmane","family":"Faye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amadou Alpha","family":"Sall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mawlouth","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumar","family":"Faye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Fausther-Bovendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7346294","DOI":"10.1155\/2016\/7346294","article-title":"Safety and efficacy profile of commercial veterinary vaccines against rift valley fever: A review study","volume":"2016","author":"Alhaj","year":"2016","journal-title":"J. Immunol. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41541-023-00769-w","article-title":"Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates","volume":"8","author":"Alkan","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1016\/j.vaccine.2021.10.008","article-title":"A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity","volume":"39","author":"Babuadze","year":"2021","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e725","DOI":"10.1371\/journal.pntd.0000725","article-title":"Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus","volume":"4","author":"Bhardwaj","year":"2010","journal-title":"PloS Negl. Trop. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-018-0052-x","article-title":"A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting","volume":"3","author":"Chrun","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41583-023-00733-4","article-title":"Cell death and inflammation in neurodegenerative diseases","volume":"25","author":"Connors","year":"2024","journal-title":"Nat Rev Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12571-024-01509-1","article-title":"The nutritional feed gap: Seasonal variations in ruminant nutrition and knowledge gaps in relation to food security in Southern Africa","volume":"17","author":"Cooke","year":"2025","journal-title":"Food Secur."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e28700","DOI":"10.1002\/jmv.28700","article-title":"Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials","volume":"95","author":"Dia","year":"2023","journal-title":"J. Med. Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41541-022-00551-4","article-title":"Immune correlates of protection following Rift Valley fever virus vaccination","volume":"7","author":"Doyle","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/vbz.2014.1650","article-title":"A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep","volume":"14","author":"Faburay","year":"2014","journal-title":"Vector. Borne. Zoonotic. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1038\/s41598-017-04027-0","article-title":"A Rift Valley fever virus Gn ectodomain-based DNA vaccine confers protection in sheep","volume":"7","author":"Faburay","year":"2017","journal-title":"Scientific Reports"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-022-03271-3","article-title":"Acute respiratory distress syndrome: new definition, current and future therapeutic options","volume":"20","author":"Fanelli","year":"2022","journal-title":"J Transl Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/v11090796","article-title":"The one health approach in the context of Rift Valley fever virus infection: a comprehensive review","volume":"11","author":"Fawzy","year":"2019","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1016\/j.vaccine.2023.10.027","article-title":"Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO\/MPP mRNA Technology Transfer Programme meeting report","volume":"41","author":"Gsell","year":"2023","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol. Infect."},{"key":"B17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0007314","DOI":"10.1371\/journal.pntd.0007314","article-title":"Towards harmonisation of entomological surveillance in the Mediterranean area","volume":"13","author":"Jourdain","year":"2019","journal-title":"PloS Negl. Trop. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10393-016-1192-y","article-title":"Public health benefits from livestock rift valley fever control: A simulation of two epidemics in Kenya","volume":"13","author":"Kimani","year":"2016","journal-title":"Ecohealth"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/14760584.2023.2292772","article-title":"The use of electroporation to deliver DNA-based vaccines","volume":"23","author":"Kisakov","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12879-022-07350-9","article-title":"Spatiotemporal patterns and environmental drivers of Rift Valley fever outbreaks in East Africa, 2000\u20132020","volume":"22","author":"Kitandwe","year":"2022","journal-title":"BMC Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/fvl.10.63","article-title":"Towards a safe, effective vaccine for Rift Valley fever virus","volume":"5","author":"Labeaud","year":"2010","journal-title":"Future Virol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj0611","article-title":"Novel suction-based in vivo cutaneous DNA transfection platform","volume":"7","author":"Lallow","year":"2021","journal-title":"Sci. Adv."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fenvs.2022.931299","article-title":"Dry season forage assessment across Senegalese rangelands using earth observation data","author":"Lo","year":"2022","journal-title":"Front. Environ. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed8020087","article-title":"Human and livestock surveillance revealed the circulation of rift valley fever virus in Agnam, Northern Senegal 2021","volume":"8","author":"Mhamadi","year":"2023","journal-title":"Trop. Med. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100060","DOI":"10.1016\/j.jvacx.2020.100060","article-title":"Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile","volume":"5","author":"Monath","year":"2020","journal-title":"Vaccine X."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12091174","article-title":"Rift valley fever virus-infection, pathogenesis and host immune responses","volume":"12","author":"Nair","year":"2023","journal-title":"Pathogens"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/tmi.12385","article-title":"Risk factors associated with human Rift Valley fever infection: systematic review and meta-analysis","volume":"19","author":"Nicholas","year":"2014","journal-title":"Trop. Med. Int. Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0012347","DOI":"10.1371\/journal.pntd.0012347","article-title":"The socioeconomic impacts of Rift Valley fever: A rapid review","volume":"18","author":"O\u2019Neill","year":"2024","journal-title":"PloS Negl. Trop. Dis."},{"key":"B31","volume-title":"Target Product Profiles for Rift Valley Fever Virus Vaccines","year":"2019"},{"key":"B32","volume-title":"Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.779858","article-title":"Safety, immunogenicity and antibody persistence of rift valley fever virus clone 13 vaccine in sheep, goats and cattle in Tanzania","volume":"8","author":"Sindato","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100583","DOI":"10.1016\/j.onehlt.2023.100583","article-title":"Rift Valley fever in West Africa: A zoonotic disease with multiple socio-economic consequences","volume":"17","author":"Tinto","year":"2023","journal-title":"One Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jcv.2007.10.001","article-title":"Rapid detection of important human pathogenic Phleboviruses","volume":"41","author":"Weidmann","year":"2008","journal-title":"J. Clin. Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41541-020-00271-7","article-title":"A single vaccination with four-segmented rift valley fever virus prevents vertical transmission of the wild-type virus in pregnant ewes","volume":"6","author":"Wichgers Schreur","year":"2021","journal-title":"NPJ Vaccines."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110817118","article-title":"An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination","volume":"118","author":"Xia","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1628877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:28:02Z","timestamp":1756186082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1628877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":38,"alternative-id":["10.3389\/fcimb.2025.1628877"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1628877","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1628877"}}